Damora Therapeutics

DMRA

Capitalización de mercado USD 1138 M

BOSTON, Oct. 02, 2026 (GLOBE NEWSWIRE) -- Damora Therapeutics, Inc. (NASDAQ: DMRA) (“Damora”), a biotechnology company working to fundamentally redefine care for patients with blood disorders, today announced that it granted equity awards to five newly-hired, non-executive employees on October 1, 2026. The inducement grants were approved by Damora's independent Compensation Committee of its Board of Directors and were made as material inducements to such individuals' acceptance of employment with Damora in accordance with Nasdaq Listing Rule 5635(c)(4).

BOSTON, Sept. 03, 2026 (GLOBE NEWSWIRE) -- Damora Therapeutics, Inc. (NASDAQ: DMRA) (“Damora”), a biotechnology company working to fundamentally redefine care for patients with blood disorders, today announced that it granted equity awards to three newly-hired, non-executive employees on September 1, 2026.

Damora Therapeutics is advancing a differentiated portfolio targeting mutant calreticulin (mutCALR) in ET and MF, with three escalating mechanism programs. DMRA's lead candidate, DMR-001, offers up to 30x potency and 5x half-life over comparators, supporting convenient monthly subcutaneous dosing. CLARITY-101 trial design accelerates clinical evaluation, with proof-of-concept data expected mid-2027 and Phase 3 potentially starting mid-2028.

-- DMR-001 is a highly potent, long-acting antibody therapy targeting Type 1 and non-Type 1 mutant calreticulin (mutCALR), designed for convenient once-monthly subcutaneous dosing -- -- In preclinical studies, DMR-001 demonstrated up to 30-fold greater potency and an approximately five-fold longer half-life than a reference anti-mutCALR antibody, supporting its best-in-class potential -- WALTHAM, Mass., Aug. 05, 2026 (GLOBE NEWSWIRE) -- Damora Therapeutics, Inc. (NASDAQ: DMRA), a biotechnology company working to fundamentally redefine care for patients with blood disorders, today announced the initiation of the global Phase 1/1b CLARITY-101 clinical trial of DMR-001, an investigational monoclonal antibody therapy designed to selectively target mutant calreticulin (mutCALR), in patients with mutCALR-driven essential thrombocythemia (ET) and myelofibrosis (MF), based on receipt of health authority approval.

BOSTON, Aug. 03, 2026 (GLOBE NEWSWIRE) -- Damora Therapeutics, Inc. (NASDAQ: DMRA) (“Damora”), a biotechnology company working to fundamentally redefine care for patients with blood disorders, today announced that it granted equity awards to six newly-hired, non-executive employees on August 1, 2026. The inducement grants were approved by Damora's independent Compensation Committee of its Board of Directors and were made as material inducements to such individuals' acceptance of employment with Damora in accordance with Nasdaq Listing Rule 5635(c)(4).

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our analyst ratings page.

BOSTON, July 17, 2026 (GLOBE NEWSWIRE) -- Damora Therapeutics, Inc. (Damora or the Company) (NASDAQ: DMRA), a biotechnology company working to fundamentally redefine care for patients with blood disorders, today announced the completion of the redomestication of the Company from the State of Delaware to the Cayman Islands, effective on July 16, 2026. Each outstanding share of the Delaware Company's common stock automatically converted into one ordinary share, par value $0.00001 per share, of the Company, and each outstanding share of any series of the Delaware Company's preferred stock automatically converted into one outstanding share of the corresponding series of the preferred shares of the Company. The redomestication was previously approved by the Company's board of directors and subsequently approved by the stockholders of the Company at a Special Meeting of Stockholders held on February 9, 2026.

BOSTON, July 01, 2026 (GLOBE NEWSWIRE) -- Damora Therapeutics, Inc. (NASDAQ: DMRA) (“Damora”), a biotechnology company working to fundamentally redefine care for patients with blood disorders, today announced that it granted equity awards to nine newly-hired, non-executive employees on July 1, 2026. The inducement grants were approved by Damora's independent Compensation Committee of its Board of Directors and were made as material inducements to such individuals' acceptance of employment with Damora in accordance with Nasdaq Listing Rule 5635(c)(4).

BOSTON, June 01, 2026 (GLOBE NEWSWIRE) -- Damora Therapeutics, Inc. (NASDAQ: DMRA) (“Damora”), a biotechnology company working to fundamentally redefine care for patients with blood disorders, today announced that it granted equity awards to six newly-hired, non-executive employees on June 1, 2026. The inducement grants were approved by Damora's independent Compensation Committee of its Board of Directors and were made as material inducements to such individuals' acceptance of employment with Damora in accordance with Nasdaq Listing Rule 5635(c)(4).

Damora Therapeutics is focused on mutant-CALR blood diseases, with DMR-001 as its lead asset. They have approximately $562.3 million in cash, and management believes this gives them enough runway into 2029. DMRA's lead asset has potential competitors in more advanced R&D stages. This helps validate the asset class as a whole, but DMRA still needs more data of its own.